Shares of Novavax (NASDAQ: NVAX) rallied in early morning trading on Tuesday as the biotechnology company announced that it would make available 1 million doses of its COVID-19 vaccine, Nuvaxovid (NVX-CoV2373) in the UK.
The company stated that Nuvaxovid is the first protein-based COVID-19 vaccine that has been granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and will be offered by the Joint Committee on Vaccination and Immunisation (JCVI) in the UK.
